title: Bevacizumab in recurrent glioblastoma: open issues.
abstract: Recurrent glioblastoma represents a challenge in neuro-oncology since the prognosis is poor and current therapeutic options are limited. Bevacizumab has demonstrated activity in this setting in various clinical trials and has been approved by US FDA for the treatment of recurrent glioblastoma. Nevertheless, many issues still exist. In this article, we summarized the principal subjects of controversies that surround bevacizumab and its use in the treatment of recurrent glioblastoma.
authors.affiliation: Department of Medical Oncology, Azienda USL, Bellaria Hospital - IRCCS Institute of Neurological Sciences, Bologna, Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: Franceschi
authors.affiliation: Department of Medical Oncology, Azienda USL, Bellaria Hospital - IRCCS Institute of Neurological Sciences, Bologna, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Bartolotti
authors.affiliation: Department of Medical Oncology, Azienda USL, Bellaria Hospital - IRCCS Institute of Neurological Sciences, Bologna, Italy.
authors.forename: Alba A
authors.initials: AA
authors.lastname: Brandes
keywords: anti-angiogenic; bevacizumab; glioblastoma; recurrent